{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:33:18Z","timestamp":1785897198360,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA056438-01"],"award-info":[{"award-number":["R01DA056438-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA057284-01"],"award-info":[{"award-number":["R01DA057284-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K08DA048110-04"],"award-info":[{"award-number":["K08DA048110-04"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gorman Scholar Award, University of Michigan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11606-024-08819-2","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T11:14:31Z","timestamp":1718709271000},"page":"2160-2168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association Between Cost-Sharing and Buprenorphine Prescription Abandonment"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-272X","authenticated-orcid":false,"given":"Kao-Ping","family":"Chua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena M.","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Lagisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S. B.","family":"Bohnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Nuliyalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy D.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"8819_CR1","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. https:\/\/doi.org\/10.17226\/25310.","DOI":"10.17226\/25310"},{"issue":"3","key":"8819_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137-145. \nhttps:\/\/doi.org\/10.7326\/M17-3107.","journal-title":"Ann Intern Med."},{"key":"8819_CR3","doi-asserted-by":"publisher","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https:\/\/doi.org\/10.1136\/bmj.j1550.","DOI":"10.1136\/bmj.j1550"},{"key":"8819_CR4","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2022 National Survey on Drug Use and Health. 2023. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt42731\/2022-nsduh-nnr.pdf.\u00a0Accessed 15 May 2024."},{"issue":"16","key":"8819_CR5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1001\/jama.2023.1207","volume":"329","author":"KP Chua","year":"2023","unstructured":"Chua KP, Nguyen TD, Zhang J, Conti RM, Lagisetty P, Bohnert AS. Trends in buprenorphine initiation and retention in the United States, 2016-2022. JAMA. 2023;329(16):1402-1404. https:\/\/doi.org\/10.1001\/jama.2023.1207.","journal-title":"JAMA."},{"issue":"4","key":"8819_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.adaj.2021.01.001","volume":"152","author":"KP Chua","year":"2021","unstructured":"Chua KP, Hu HM, Waljee JF, Brummett CM, Nalliah RP. Opioid prescribing patterns by dental procedure among US publicly and privately insured patients, 2013 through 2018. J Am Dent Assoc. 2021;152(4):309-317. \nhttps:\/\/doi.org\/10.1016\/j.adaj.2021.01.001.","journal-title":"J Am Dent Assoc."},{"key":"8819_CR7","doi-asserted-by":"publisher","unstructured":"Chandra A, Flack E, Obermeyer Z. The health costs of cost-sharing. NBER Working Paper 28439. 2021; https:\/\/doi.org\/10.3386\/w28439.","DOI":"10.3386\/w28439"},{"issue":"3","key":"8819_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1257\/pol.20160355","volume":"10","author":"L Einav","year":"2018","unstructured":"Einav L, Finkelstein A, Polyakova M. Private provision of social insurance: drug-specific price elasticities and cost sharing in Medicare Part D. Am Econ J Econ Policy. 2018;10(3):122-153. \nhttps:\/\/doi.org\/10.1257\/pol.20160355.","journal-title":"Am Econ J Econ Policy."},{"key":"8819_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jsat.2019.08.001","volume":"106","author":"C McClellan","year":"2019","unstructured":"McClellan C, Fingar KR, Ali MM, Olesiuk WJ, Mutter R, Gibson TB. Price elasticity of demand for buprenorphine\/naloxone prescriptions. J Subst Abuse Treat. 2019;106:4-11. https:\/\/doi.org\/10.1016\/j.jsat.2019.08.001.","journal-title":"J Subst Abuse Treat."},{"issue":"9","key":"8819_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1001\/jamainternmed.2023.2826","volume":"183","author":"AA Leech","year":"2023","unstructured":"Leech AA, McNeer E, Roberts AW, et al. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder. JAMA Intern Med. 2023;183(9):1023-1026. https:\/\/doi.org\/10.1001\/jamainternmed.2023.2826.","journal-title":"JAMA Intern Med."},{"key":"8819_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108784","volume":"225","author":"C Dunphy","year":"2021","unstructured":"Dunphy C, Peterson C, Zhang K, Jones CM. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder? Drug Alcohol Depend. 2021;225:108784. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108784.","journal-title":"Drug Alcohol Depend."},{"key":"8819_CR12","unstructured":"STROBE Guidelines. https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/. Accessed 02\/13, 2021."},{"key":"8819_CR13","unstructured":"Kaiser Family Foundation. Premium and cost-sharing requirements for selected services for medicaid Adults. https:\/\/www.kff.org\/affordable-care-act\/state-indicator\/premium-and-cost-sharing-requirements-for-selected-services-for-medicaid-expansion-adults. Accessed 25 March 2024."},{"key":"8819_CR14","doi-asserted-by":"publisher","unstructured":"Terranella A, Guy GP, Mikosz C. Buprenorphine dispensing among youth aged <\/=19 years in the United States: 2015\u20132020. Pediatrics. 2023;151(2). https:\/\/doi.org\/10.1542\/peds.2022-058755.","DOI":"10.1542\/peds.2022-058755"},{"issue":"10","key":"8819_CR15","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/hec.4379","volume":"30","author":"K Kosec","year":"2021","unstructured":"Kosec K, Song J. The effects of income fluctuations on undernutrition and overnutrition across the lifecycle. Health Economics. 2021;30(10):2487-2509. https:\/\/doi.org\/10.1002\/hec.4379.","journal-title":"Health Economics."},{"key":"8819_CR16","doi-asserted-by":"publisher","unstructured":"Norton EC, Dowd BE, Maciejewski ML. Marginal effects-quantifying the effect of changes in risk factors in logistic regression models. JAMA. 2019;321(13):1304\u20131305.:https:\/\/doi.org\/10.1001\/jama.2019.1954.","DOI":"10.1001\/jama.2019.1954"},{"issue":"11","key":"8819_CR17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","volume":"2","author":"AM Navar","year":"2017","unstructured":"Navar AM, Taylor B, Mulder H, et al. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. JAMA Cardiol. 2017;2(11):1217-1225. https:\/\/doi.org\/10.1001\/jamacardio.2017.3451.","journal-title":"JAMA Cardiol."},{"issue":"5","key":"8819_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1200\/JCO.2017.74.5091","volume":"36","author":"JA Doshi","year":"2018","unstructured":"Doshi JA, Li P, Huo H, Pettit AR, Armstrong KA. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents. J Clin Oncol. 2018;36(5):476-482. https:\/\/doi.org\/10.1200\/JCO.2017.74.5091.","journal-title":"J Clin Oncol."},{"issue":"10","key":"8819_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.7326\/0003-4819-153-10-201011160-00005","volume":"153","author":"WH Shrank","year":"2010","unstructured":"Shrank WH, Choudhry NK, Fischer MA, et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010;153(10):633-40. https:\/\/doi.org\/10.7326\/0003-4819-153-10-201011160-00005.","journal-title":"Ann Intern Med."},{"key":"8819_CR20","unstructured":"IQVIA Institute for Human Data Science. The use of medicines in the U.S.: spending and usage trends and outlook to 2027. 2023. Parisippany, NJ: IQVIA Institute for Human Data Science. https:\/\/www.iqvia.com\/insights\/the-iqviainstitute\/reports-and-publications\/reports\/the-use-of-medicines-in-the-us-2023."},{"issue":"11","key":"8819_CR21","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/pds.5334","volume":"30","author":"ME Buttram","year":"2021","unstructured":"Buttram ME, Kurtz SP, Margolin ZR, Severtson SG. Increasing rates of buprenorphine diversion in the United States, 2002 to 2019. Pharmacoepidemiol Drug Saf. 2021;30(11):1514-1519. doi:\nhttps:\/\/doi.org\/10.1002\/pds.5334.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"8819_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/ADM.0000000000000436","volume":"12","author":"JJ Carroll","year":"2018","unstructured":"Carroll JJ, Rich JD, Green TC. The more things change: buprenorphine\/naloxone diversion continues while treatment remains inaccessible. J Addict Med. 2018;12(6):459-465. https:\/\/doi.org\/10.1097\/ADM.0000000000000436.","journal-title":"J Addict Med."},{"key":"8819_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106105","volume":"137","author":"Y Hswen","year":"2020","unstructured":"Hswen Y, Zhang A, Brownstein JS. Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018. Prev Med. 2020;137:106105. https:\/\/doi.org\/10.1016\/j.ypmed.2020.106105.","journal-title":"Prev Med."},{"key":"8819_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","volume":"95","author":"H Samples","year":"2018","unstructured":"Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9-17. https:\/\/doi.org\/10.1016\/j.jsat.2018.09.001.","journal-title":"J Subst Abuse Treat."},{"issue":"7","key":"8819_CR25","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1176\/appi.ps.201700363","volume":"69","author":"A Manhapra","year":"2018","unstructured":"Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768-776. https:\/\/doi.org\/10.1176\/appi.ps.201700363.","journal-title":"Psychiatr Serv."},{"issue":"3","key":"8819_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jamainternmed.2016.8411","volume":"177","author":"JF Wharam","year":"2017","unstructured":"Wharam JF, Zhang F, Eggleston EM, Lu CY, Soumerai S, Ross-Degnan D. Diabetes outpatient care and acute complications before and after high-deductible insurance enrollment: a natural experiment for translation in diabetes (NEXT-D) study. JAMA Intern Med. 2017;177(3):358-368. https:\/\/doi.org\/10.1001\/jamainternmed.2016.8411.","journal-title":"JAMA Intern Med."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-08819-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-024-08819-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-08819-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:05:45Z","timestamp":1764266745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-024-08819-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["8819"],"URL":"https:\/\/doi.org\/10.1007\/s11606-024-08819-2","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"29 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"Dr. Chua reports receiving consulting fees from the U.S. Department of Justice. No other conflicts of interest were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}